Center for Biologics Evaluation and Research Director Peter Marks confirmed that the US Food and Drug Administration likely will employ the emergency use authorization pathway to make a coronavirus vaccine available, but with the more stringent safety and efficacy standards typical for full licensure.
Marks characterized the approach as “emergency use authorization plus” during a 10 September virtual Duke-Margolis Center for Health Policy meeting on safe and effective COVID-19 vaccination